Ask an industry onlooker what the following companies have in common – Teva, Viatris, Apotex, Fresenius Kabi, Hikma, Zentiva, Alvotech, Nichi-Iko, Biocon Biologics and Padagis – and they might answer that these firms are among the leading generics and biosimilars players around the world.
While this is accurate, a further characteristic that these firms share is that within the last few months, they have all either implemented or announced leadership changes at the very top of their organization – with such a rapid turnover of leading executives suggesting that fresh strategies and new